The biggest challenge facing Wes Streeting over scandalous state of maternity services
This was a powerful speech from the health secretary who is clearly troubled by the scandalous state of maternity services in this country.
Wes Streeting has spent the past year meeting bereaved families who have been failed by the NHS.
He said he "was kept up at night" after listening to their harrowing testimonies.
Announcing a national investigation into NHS maternity services, this review is modelled on the Darzi report into the NHS, commissioned by the health secretary almost as soon as he came into office.
It . The terms of reference for the investigation will be known by July. The actual report is expected to be published by Christmas.
Mr Streeting accepts this is an ambitious timeline but is driven by the fear that mothers and babies are still being failed and he does not want "any deaths on his watch".
And he has not ruled out a future public inquiry, which is what the bereaved families have been demanding.
The biggest challenge for the health secretary will be to change the culture within maternity units.
This has been identified as one of the biggest issues in previous reports by Bill Kirkup and Donna Ockenden.
It's why, Mr Streeting said, he chose to make his announcement at the Royal College of Obstetricians and Gynaecologists' World Congress Day.
What he said would have made for uncomfortable listening for some delegates but he needs them on board to deliver on his promise to make maternity and neonatal care safe.
Read more from Sky News:
The health secretary clearly has empathy. He has listened to the families torn apart by maternity failings.
But if there is any criticism of his action, it is that it could have been taken sooner, up to six months ago.
The failures across maternity services up and down the country have been known about for a long time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Mounjaro becomes available on the NHS: what to know and what to do if you're not eligible
Obesity remains one of the most pressing, and preventable, health challenges of our time. The UK is one of a number of countries undoubtedly struggling with it. It affects nearly every organ system in the body, contributing to cardiovascular conditions like coronary heart disease; musculoskeletal issues such as osteoarthritis and gout; and even the development of certain cancers, including of the breast, uterus and colon. Its impact on mental health is also significant. A few years ago, injectable weight-loss drugs entered clinical use and quickly captured public attention for their ability to promote rapid fat loss. Ozempic is available on the NHS, but only for managing type 2 diabetes. Wegovy is authorised for weight loss and cardiovascular risk reduction and is also available on the NHS, though access is currently limited to specialist weight management services. Now, a new option has emerged: Mounjaro, which is approved for both type 2 diabetes and weight loss. This dual-purpose drug is now available on the NHS, offering another potential tool in the fight against obesity. Demand is expected to be high. However, access will be limited at first, with strict eligibility criteria for NHS prescriptions. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Mounjaro (tirzepatide) is a once weekly injectable medication designed to help control blood-sugar levels. It works by boosting the secretion and effects of insulin, improving glycaemic control in people with Type 2 diabetes. It also slows gastric emptying — the process by which food leaves the stomach — and enhances feelings of fullness by acting on the brain. This combined effect reduces appetite and helps support weight loss. Compared to similar medications like Ozempic and Wegovy (both brand names for semaglutide), clinical trials found Mounjaro more effective, with some participants losing up to 20% of their body weight over a 72-week period. Read more: The NHS has introduced specific criteria to prioritise patients most in need. First, patients need a BMI of 40 or more (classified as morbid obesity). People from certain ethnic backgrounds, such as South Asian communities, may be eligible at a lower BMI due to higher clinical risk of health conditions. Second, at least four obesity-related health conditions must be diagnosed, including type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglyceride levels), cardiovascular disease and obstructive sleep apnoea. (Some of these conditions often occur together; for example, high blood pressure and cholesterol.) Patients are encouraged to check their BMI and confirm their diagnoses before contacting a GP. This helps ensure appointments are used effectively and discussions remain focused. While the current criteria are strict, there is optimism that eligibility will broaden in the coming years to include people with lower BMIs and fewer co-morbidities. The NHS continues to offer a comprehensive weight-loss programme, tiered according to BMI and previous attempts at weight loss. Don't underestimate the value of group-based programmes or community referrals – when a healthcare professional refers a patient to a community-based health service for further care or support – many of which can be accessed via your GP. These services, such as the NHS digital weight management programme, support both individuals and families and can be highly effective for sustainable fat loss. GPs may also refer patients to online courses and structured exercise programmes. Lifestyle interventions, including increased physical activity and healthier eating, remain cornerstones of obesity treatment and are critical for long-term success, even when medications are used. Read more: Higher tier interventions may be considered if lifestyle changes fail or if the patient has significant co-morbidities. This is where medications like Mounjaro, or private prescriptions, may become relevant – albeit that the cost of the latter may be a limiting factor for some. Other treatments include Orlistat, a medication that reduces fat absorption in the gut. This can be effective for some but often causes unpleasant side effects, such as oily stools and gastrointestinal upset Gastric banding or surgery may also result in significant, sustained weight loss, but they come with risks, can lead to surgical complications, and recovery can be demanding It's also important to recognise that drugs like Mounjaro aren't suitable for everyone. They can cause side effects significant enough for people to stop using them, and in some cases, they may not work at all. In this new era of faster, medication-assisted weight loss, we must remember that long-term change is about more than quick fixes. Sustainable success comes from consistent effort, willingness to change and methods that are both practical and lasting. Medications can help, sometimes dramatically, but they're not the only answer. A return to basics, with tailored support and realistic goals, remains as relevant as ever. So whether you qualify for Mounjaro, are trying lifestyle changes, or are exploring other options, remember this: the journey to better health is personal, gradual and worth it. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Associated Press
2 hours ago
- Associated Press
Benchmark Data for Dealmakers - Access Deal Records of Actual Deals As Disclosed by the Deal Parties
DUBLIN--(BUSINESS WIRE)--Jun 23, 2025-- The 'Precision Medicine Collaboration and Licensing Deals 2019-2025" has been added to offering. This report contains a comprehensive listing of 1,221 precision medicine deals announced since 2019, including financial terms where available, and links to online deal records of actual precision medicine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Precision Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of precision medicine deals from 2019 to 2025. The report provides a detailed understanding and analysis of how and why companies enter precision medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals. The initial chapters of the report offer an overview of precision medicine dealmaking. Chapter 1 serves as an introduction, while Chapter 2 outlines the trends in precision medicine dealmaking since 2019. Chapter 3 highlights leading precision medicine deals by headline value, and Chapter 4 lists the top 25 most active companies with summaries and listings of deals. Chapters 5 and 6 provide detailed reviews of deals announced since Jan 2019, organized by contractor availability and technology focus respectively. Precision Medicine Collaboration and Licensing Deals provides the reader with the following key benefits: Precision Medicine Collaboration and Licensing Deals includes: Analyzing contract agreements allows due diligence of: Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in precision medicine dealmaking 2.1. Introduction 2.2. Precision medicine deals over the years 2.3. Most active precision medicine dealmakers 2.4. Precision medicine deals by deal type 2.5. Precision medicine deals by therapy area 2.6. Precision medicine deals by industry sector 2.7. Deal terms for precision medicine deals 2.7.1 Precision medicine deals headline values 2.7.2 Precision medicine deal upfront payments 2.7.3 Precision medicine deal milestone payments 2.7.4 Precision medicine royalty rates Chapter 3 - Leading precision medicine deals 3.1. Introduction 3.2. Top precision medicine deals by value Chapter 4 - Most active precision medicine dealmakers 4.1. Introduction 4.2. Most active precision medicine dealmakers 4.3. Most active precision medicine deals company profiles Chapter 5 - Precision medicine contracts dealmaking directory 5.1. Introduction 5.2. Precision medicine contracts dealmaking directory Chapter 6 - Precision medicine dealmaking by technology type Deal directory Companies Featured For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/23/2025 01:09 PM/DISC: 06/23/2025 01:08 PM
Yahoo
2 hours ago
- Yahoo
First look inside new gym in north Norfolk
A new gym is opening in north Norfolk this week. With five years of experience as a personal trainer, Josh Willis and sports coach Hannah Carter are opening Carter's Gym in North Walsham on Saturday. The pair saw a "gap in the market" for weight space gyms in the area that are not bodybuilding-focused. The gym is located in Unit 16 in Robertson House (Image: Denise Bradley) The new space hopes to target those who lack confidence surrounding the use of weights. "I have a good clientele at the moment who will be joining me over here and I will continue to offer friendly service to help build people's confidence," Mr Willis said. 'We have received a really good response so far and now it is finally kicking in, the excitement is building." The gym specialises in weight training (Image: Denise Bradley) Gym goers can expect a range of weight equipment as well as cardio machines. Personal training sessions and small group classes limited to eight people to ensure "a more personalised experience" will also be on offer. "With it just being the two of us at the moment, we are a gym for our members,' Ms Carter added. Gymgoers will be able to try out the new equipment for free from 10am to 4pm on opening day (Image: Denise Bradley) "We will act on our members' feedback as we want to show them that their money is being put back into the gym." Carter's Gym is located in Unit 16 Robertson House in Laundry Loke. A monthly direct debit membership is on offer for £28.99, small group training sessions for members cost £6 and personal training is £30 an hour. Personal trainer Josh will be bringing his expertise to the new space (Image: Denise Bradley) Gymgoers will be able to try out the new equipment for free by attending the opening between 10am and 4pm on Saturday. Those who attend will be entered into a free raffle to win prizes, including a month's membership.
